News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Opinion|Videos|September 11, 2024

Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

Author(s)Barbara Burtness, MD, Victoria M. Villaflor, MD, Shravan Kandula, MD

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

Episodes in this series

A panel of 3 experts on nasopharyngeal carcinoma

EP. 1 Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

A panel of 3 experts on nasopharyngeal carcinoma

EP. 2 Current Guidelines for Managing Nasopharyngeal Carcinoma

A panel of 3 experts on nasopharyngeal carcinoma

EP. 3 Overview of the JUPITER and POLARIS-2 Trials

A panel of 3 experts on nasopharyngeal carcinoma

EP. 4 Value of PD-L1 Biomarker in NPC

A panel of 3 experts on nasopharyngeal carcinoma

EP. 5 Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

A panel of 3 experts on nasopharyngeal carcinoma

EP. 6 Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

A panel of 3 experts on nasopharyngeal carcinoma

EP. 7 Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

A panel of 3 experts on nasopharyngeal carcinoma

EP. 8 Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

A panel of 3 experts on nasopharyngeal carcinoma

EP. 9 Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

A panel of 3 experts on nasopharyngeal carcinoma

EP. 10 Clinical Scenario: Locally Recurrent NPC

A panel of 3 experts on nasopharyngeal carcinoma

EP. 11 Clinical Scenario: Metastatic EBV-Positive NPC

Video content above is prompted by the following:

What strategies would you implement to mitigate potential adverse events?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

HNSCC | Image Credit: © G.Go - stock.adobe.com

July 8th, 2026

Neoadjuvant/Adjuvant Pembrolizumab Yields EFS Benefits Regardless of Surgical Outcomes in HNSCC

Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.

Trending on OncLive

FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma

Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer

Dive Into Key Data and Presentations From EHA 2026

Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma

Dr Jabbour on the Significance of the FDA Approval of Orally Disintegrating Nilotinib Tablets for CML